SCHEMBL17972355

SCHEMBL17972355

CO[C@@H]1C(O)[C@H](n2cnc3c(N)ncnc32)O[C@@H]1CO

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 4/20 0.75
▸ ADORA1 P30542 3/20 0.75
▸ SMN1; SMN2 Q16637 2/20 0.75
▸ PI4KA P42356 2/20 0.75
▸ PI4K2B Q8TCG2 2/20 0.75
▸ PI4K2A Q9BTU6 2/20 0.75
▸ PI4KB Q9UBF8 2/20 0.75
▸ DPP4 P27487 1/20 0.75
▸ MEN1 O00255 1/20 0.75
▸ SLC28A1 O00337 1/20 0.75
▸ MAP3K7 O43318 1/20 0.75
▸ SLC28A2 O43868 1/20 0.75
▸ GAPDH P04406 1/20 0.75
▸ MAPK1 P28482 1/20 0.75
▸ ADORA2A P29274 1/20 0.75
▸ ADORA2B P29275 1/20 0.75
▸ STAT6 P42226 1/20 0.75
▸ KMT2A Q03164 1/20 0.75
▸ DOT1L Q8TEK3 1/20 0.75
▸ SLC29A1 Q99808 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21418864 1.00 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2PI4KAPI4K2B
SCHEMBL29748808 1.00 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2PI4KAPI4K2B
SCHEMBL7148261 1.00 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2PI4KAPI4K2B
SCHEMBL3369124 1.00 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2PI4KAPI4K2B
SCHEMBL1066939 1.00 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2PI4KAPI4K2B
SCHEMBL23547979 1.00 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2PI4KAPI4K2B
SCHEMBL16359953 1.00 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2PI4KAPI4K2B
SCHEMBL16724749 1.00 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2PI4KAPI4K2B
SCHEMBL25936 0.91 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2PI4KAPI4K2B
SCHEMBL24538798 0.91 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11857560-B2 Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections EMORY UNIVERSITY (US) 2024-01-02 — — US disclosed
US-20160220595-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO DEFENSE THREAT REDUCTION AGENCY, US DOD 2016-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160220595-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO PNP, NTPCR, TYMP ADORA3 114/4885ADORA1 133/4885SMN1; SMN2 1254/4885
US-11857560-B2 Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections SLC28A1, PNP, SLC28A2 ADORA3 26/4885ADORA1 17/4885SMN1; SMN2 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback